Similar articles

• The third analysis of the bicalutamide Early Prostate Cancer programme.

  Iversen P; Early Prostate Cancer Programme Investigators. Iversen P, et al. BJU Int. 2006 Mar;97(3):438-9. doi: 10.1111/j.1464-410X.2006.06118.x. BJU Int. 2006. PMID: 16469002 No abstract available.
• Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.

  Sternberg CN. Sternberg CN. BJU Int. 2006 Mar;97(3):435-8. doi: 10.1111/j.1464-410X.2006.06088.x. BJU Int. 2006. PMID: 16469001 No abstract available.
• Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

  McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. McLeod DG, et al. BJU Int. 2006 Feb;97(2):247-54. doi: 10.1111/j.1464-410X.2005.06051.x. BJU Int. 2006. PMID: 16430622 Clinical Trial.
• [The role of bicalutamide in the treatment of prostate cancer].

  Stav SY, Segal G. Stav SY, et al. Harefuah. 2002 Apr;141(4):379-83, 408, 407. Harefuah. 2002. PMID: 12017896 Review. Hebrew.
• [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].

  Sivko AV, Prokhorov AV. Sivko AV, et al. Urol Nefrol (Mosk). 1997 May-Jun;(3):49-52. Urol Nefrol (Mosk). 1997. PMID: 9245060 Review. Russian. No abstract available.